Regeneron Pharmaceuticals Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.69. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SJNK | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Sector/Thematic |
52-Week High | $852.03 | $25.63 |
52-Week Low | $555.51 | $24.67 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.70 with minimal daily movement (-0.04%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral. The ETF continues its regular dividend distributions, with recent payments of $0.14-0.15 per share. Institutional activity shows mixed sentiment with some firms reducing positions.
The outlook remains cautious given the bearish technical signals and institutional selling pressure. While the ETF provides consistent dividend income, high-yield bond markets face headwinds from potential yield increases and economic uncertainty. Investors should weigh the income generation against credit risk exposure in the current market environment.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →